Omnicell/$OMCL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Omnicell
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
- Ticker
- $OMCL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,485
- Headquarters
- Fort Worth, United States
- Website
- www.omnicell.com
Omnicell Metrics
BasicAdvanced
$1.7B
38.28
$0.96
-
-
Price and volume
Market cap
$1.7B
52-week high
$55.00
52-week low
$30.69
Average daily volume
526K
Financial strength
Current ratio
1.655
Quick ratio
1.163
Long term debt to equity
0.144
Total debt to equity
0.144
Interest coverage (TTM)
15.18%
Profitability
EBITDA (TTM)
101.879
Gross margin (TTM)
45.51%
Net profit margin (TTM)
3.59%
Operating margin (TTM)
5.72%
Effective tax rate (TTM)
33.57%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
2.22%
Return on equity (TTM)
3.52%
Valuation
Price to earnings (TTM)
38.279
Price to revenue (TTM)
1.347
Price to book
1.28
Price to tangible book (TTM)
3.99
Price to free cash flow (TTM)
12.863
Free cash flow yield (TTM)
7.77%
Free cash flow per share (TTM)
2.867
Growth
Revenue change (TTM)
5.62%
Earnings per share change (TTM)
126.47%
3-year revenue growth (CAGR)
1.60%
10-year revenue growth (CAGR)
6.69%
3-year earnings per share growth (CAGR)
7.93%
10-year earnings per share growth (CAGR)
16.01%
What the Analysts think about Omnicell
Analyst ratings (Buy, Hold, Sell) for Omnicell stock.
Analyst projections of the future price of Omnicell stock.
Bulls say / Bears say
Second-quarter revenue rose 7% year on year to $312 million, with growth in both connected devices and services. Growing service and software-related sales give Omnicell a larger recurring-revenue base. (Omnicell)
Omnicell raised its 2026 EBITDA and adjusted earnings-per-share outlook after better-than-expected second-quarter profitability. Management cited cost discipline and operating efficiency, suggesting it is improving earnings even as sales growth remains moderate. (Omnicell)
Evidence of customer adoption supports the growth case: Omnicell reported Titan XT selections and a competitive conversion win, while a UK hospital launched an integrated Omnicell medicines system. These deployments show demand for connected medication workflows beyond the company’s product pipeline. (Stock Analysis, University Hospitals Coventry & Warwickshire)
The 2026 product-bookings outlook has a wide $425 million to $560 million range, reflecting uncertainty over when large customer decisions will close. Long approval and contracting cycles make near-term sales visibility weak. (Omnicell)
The company’s year-end recurring-revenue outlook is $660 million to $680 million, with some consumables growth opportunities taking longer to develop than expected. That delay tempers the case that recurring sales will quickly make results more predictable. (Omnicell)
Second-quarter profit benefited from a $15 million tariff refund that will not recur, while memory-chip costs are expected to add about $6 million in the second half. Those factors make the reported earnings strength harder to sustain and could constrain margins. (Omnicell)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
Omnicell Financial Performance
Revenues and expenses
Omnicell Earnings Performance
Company profitability
Upcoming events
No upcoming events
Omnicell News
AllArticlesVideos
Funds containing Omnicell
AllUSDEURGBP
Fund name | Fund size | $OMCL weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.10% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.10% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.06% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.